Bio-Techne Corporation

NASDAQ:TECH

Biotechnology

Healthcare
$72.75 -1.84%

-$1.03 today

Market cap
$11.43B
Beta
1.36
P/E (TTM)
78.3
EPS (TTM)
$0.70
Dividend yield
0.58%
52W Low $43.20High $72.16

Volume 2.63M

Average 2.66M

TECH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Bio-Techne CorporationNASDAQ: TECH

Research & Development · Q1 FY2027 · quarter ended Sep 2026

Research & development growth accelerates

Q1 FY2027 research & development of $26.34M rose 8.7% year over year, ahead of the -3.0% change in trailing-twelve-month research & development. Sequentially, it rose 10.0% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.

Context

  • Research & development amounted to 7.8% of revenue in FY2026, down 0.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +8.7% holds above the trailing-twelve-month pace of -3.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$26.34M+10.0% QoQ
Last fiscal yearJun 2026
$94.77M-4.8% YoY
LTMSep 2026
$96.87M-3.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.7%——
1 year-4.8%——
3-year CAGR+0.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
94.77M USD
Year-over-year change
-4.8%
4-year CAGR
+2.1%

Research & Development vs competitors

How TECH compares with its peers on the latest reported figures

  • TECH's LTM Sep 2026 research & development of $96.87M is the 9th highest of the 11 companies compared; the peer median is $241.82M.
  • Its year-over-year change of -3.0% is the 7th highest of 10, against a peer median of -0.7%.
  • Research & development amounts to 7.9% of revenue for TECH, versus a peer median of 9.7%.
TECH Competitors Peer median
Research & Development for TECH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$1.67B +4.2%+1.5%6.5%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$1.41B -0.7%-1.7%3.0%
AAgilent Technologies, Inc.LTM Jul 2026$485M +8.5%-0.9%6.6%
BRKRBruker CorporationLTM Jun 2026$393.5M -1.6%+18.8%11.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
TXG10x Genomics, Inc.LTM Sep 2026$222.54M -10.9%-3.5%36.0%
RVTYRevvity, Inc.LTM Jul 2026$215.83M +5.2%-0.9%7.4%
QGENQiagen N.V.LTM Jun 2026$194.67M +5.5%-0.4%9.3%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
SEERSeer, Inc.LTM Mar 2026$41.33M -11.2%-6.2%274.8%
ALMRAlamar Biosciences, Inc.FY2025$37.47M ——50.5%
Peer median (excluding TECH) $241.82M-0.7%-0.9%9.7%

Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue1.11B1.14B1.16B1.22B1.22B
Cost of Revenue349.1M366.89M389.34M429.36M415.97M
Gross Profit756.5M769.82M769.73M790.27M799.07M
Gross Margin68.4%67.7%66.4%64.8%65.8%
Research & Development87.14M92.49M96.66M99.5M94.77M
Selling, General & Admin339M352.44M393.32M415.1M452.42M
Operating Expenses459.91M470.87M563.04M688.02M547.18M
Depreciation & Amortization101.07M107.24M111.71M109.9M97.36M
EBITDA413.76M457.11M313.14M216.88M343.44M
EBITDA Margin37.4%40.2%27.0%17.8%28.3%
Operating Income296.59M298.94M206.69M102.26M251.89M
Operating Margin26.8%26.3%17.8%8.4%20.7%
Interest Income794K3.41M3.32M3.89M0
Interest Expense11.31M11.22M15.74M8.51M5.41M
Other Income / Expenses4.8M39.72M(21M)(3.79M)(11.21M)
Income Before Tax301.39M338.66M185.69M98.46M240.68M
Pre-Tax Margin27.3%29.8%16.0%8.1%19.8%
Income Tax Expense38.29M53.22M17.58M25.06M58.82M
Net Income272.05M285.26M168.11M73.4M181.86M
Net Margin24.6%25.1%14.5%6.0%15.0%
EPS (Basic)1.731.811.070.471.17
EPS (Diluted)1.661.761.050.461.16
Weighted Avg Shares156.88M157.18M157.71M157.52M155.96M
Weighted Avg Shares (Diluted)164.12M161.86M160.77M159.72M157.01M

Bio-Techne Corporation

NASDAQ:TECH

Intrinsic Alpha fair value

Locked

Current Price

$72.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.